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Effect of Type 2 Diabetes Mellitus on the Clinical
Severity and Treatment Outcome in Patients With
Pulmonary Tuberculosis: A Potential Role in the
Emergence of Multidrug-resistance
Jenn-Tyang Chang,1,2 Horng-Yunn Dou,4 Chia-Liang Yen,1 Ying-Hsun Wu,2 Ruay-Ming Huang,2
Huey-Juan Lin,3 Ih-Jen Su,4 Chi-Chang Shieh1*
Background/Purpose: A globally increasing trend of type 2 diabetes mellitus (DM), the rising prevalence
of tuberculosis (TB) in many countries, and the emergence of multidrug-resistant TB (MDR-TB) in recent
years pose a serious challenge for TB control.
Methods: We investigated pulmonary tuberculosis patients with and without type 2 DM (DMTB and TB,
respectively) treated at the Chest Hospital, Taiwan, between November 2004 and October 2005.
Results: One hundred and ninety-two new patients (60 DMTB, 132 TB) were regularly treated for a full
course (≥ 6 months) and prospectively followed for more than 1 year. The DMTB patients had more severe
infections (far-advanced: 45.0% vs. 22.7%, p < 0.01), higher mycobacterial loads (sputum smear: 2.9 ± 1.3+
vs. 1.9 ± 1.7+, p < 0.01), higher treatment failure rates (17% vs. 2%, p < 0.01), and longer delayed clearance
of mycobacteria than did the TB patients (2.5 ± 3.0 months vs. 1.6 ± 1.4 months, p < 0.01). After one year,
three DMTB patients and one TB patient had MDR-TB (5.0% vs. 0.8%, p = 0.056). Bacterial genotyping 
revealed that the proportion of mycobacterial strains was not significantly different in DMTB and TB 
patients (Beijing strain: 46.7% vs. 40.6%, Non-Beijing strain: 53.3% vs. 59.4%, p = 0.632).
Conclusion: DMTB patients have more severe TB infections, which require longer treatment and are more
likely to develop MDR-TB than are patients with TB alone.
Key Words: Beijing strain, diabetes mellitus, multidrug-resistant tuberculosis, pulmonary tuberculosis,
spoligotype analysis
The prevalence of tuberculosis (TB) has been rising
globally in recent years, with an estimated annual
incidence of new TB cases at around nine million
and deaths at approximately two million each
year.1–3 The emergence of multidrug-resistant TB
(MDR-TB) and extensively drug-resistant TB (XDR-
TB) poses a serious challenge for future TB con-
trol.4,5 More than half the TB cases occur in Asian
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and African countries where medical resources
tend to be limited and the prevalence of MDR-TB
is alarmingly high, which makes the situation
even more difficult.1,6,7
Diabetes mellitus (DM) has been a well-known
risk factor for TB in the past.8,9 However, the in-
fluence of DM on TB was largely ignored during
the second half of the past century, after effective
treatments for both diseases became available.10
The situation has changed recently with the global
increase in the prevalence of type 2 DM, which
has penetrated developing countries.11,12 The global
convergence of the accelerating type 2 DM pan-
demic, high TB prevalence, and drug-resistant TB
during the past couple of decades has become a
serious challenge to clinicians worldwide.
Over the past few years, some studies have
shown that the treatment failure rate is higher 
in TB patients complicated with DM. Moreover,
there is a significant association between DM and
MDR-TB.13,14 However, there were controversies
regarding clinical manifestations and treatment
outcomes in diabetic patients among different
studies.15–17 In this study, we prospectively 
followed-up 192 TB and DMTB patients to deter-
mine the influence of type 2 DM on the clinical
manifestations and treatment outcomes of pul-
monary TB patients.
Patients and Methods
Patients
From November 2004 to October 2005, all pul-
monary TB patients treated at the Chest Hospital,
a central referral hospital for TB patients in Taiwan,
were investigated and classified as having pulmo-
nary TB with (DMTB) or without (TB) type 2 DM.
Pulmonary TB was diagnosed using clinical symp-
toms and chest radiographs, and confirmed using
a sputum TB culture with drug-susceptibility test-
ing in each patient. A diagnosis of type 2 DM was
confirmed when fasting plasma glucose concentra-
tion was > 126 mg/dL at two different time points.
The regimen for treating diabetes was determined
based on each patient’s specific circumstances.
Cultures for Mycobacterium tuberculosis were per-
formed using a kit (Mycobacteria Growth Indicator
Tube (MGIT) 960; Becton Dickinson Diagnostic
systems, Sparks, MD, USA) and Lowenstein-Jensen
medium. Drug-susceptibility testing was done
using proportional methods. Patients confirmed
as HIV+ were excluded. MDR-TB was defined as
pulmonary TB that was resistant to two or more
TB medications, including at least isoniazid and
rifampicin.
The age, sex, diabetic status, hemoglobin A1c
(HbA1c) before treatment, status of organ failure
[including heart failure (defined as Class III-IV of
New York Heart Association Functional Classi-
fication)], respiratory failure (defined as dyspnea
with PaO2 < 50 mmHg while breathing air, or a
PaCO2 > 50 mmHg), and renal failure (defined
as established end-stage kidney failure for > 3
months, or urine output < 0.3 mL/kg/hr for more
than 24 hr or anuria for more than 12 hr), leuko-
cyte count, severity of pulmonary TB on chest ra-
diograph, sputum-smear acid-fast bacilli (AFB),
mycobacterial load, and body mass index (BMI)
of each patient were recorded during the diag-
nostic workup and the beginning of treatment.
Modified grading of the severity of pulmonary
TB,18 according to the extent and type of chest ra-
diograph findings, divided the patients into three
groups: mild (a single lobe involved); moderately-
advanced (unilateral involvement of two or more
lobes with cavities, if present, reaching a total di-
ameter no greater than 4 cm); and far-advanced
(bilateral disease with massive involvement and
multiple cavities). The grading was checked by two
chest physicians. A Ziehl-Neelsen-stained sputum
smear was performed for microscopic examina-
tion, and the mycobacterial load was graded as +,
++, +++, or ++++.19
All TB and DMTB patients were treated with
the same recommended regimen: isoniazid, ri-
fampicin, pyrazinamide, and ethambutol in the
2-month intensive phase, and then isoniazid, ri-
fampicin, and ethambutol in the 4-month con-
tinuation phase, if the regime could be tolerated.
Because the national project of directly observed
treatment short-course (DOTS) in Taiwan had not
J.T. Chang, et al
374 J Formos Med Assoc | 2011 • Vol 110 • No 6
been implemented before 2006, the treatment was
based on self-administration. Patients were pro-
spectively followed up for at least 1 year. During
the follow-up, the period needed for sputum con-
version was documented based on the results of
monthly mycobacterial sputum cultures. The treat-
ment outcome was divided into six categories 
according to modified WHO guidelines20: cured
(finished treatment with negative bacteriology
result at the end of treatment), completed treat-
ment (finished treatment, but without bacteriology
result at the end of treatment), failure (remain-
ing culture positive at 5 months or sputum AFB
positive at 6 months despite correct intake of
medication), defaulted treatment (patients who
interrupted their treatment for two consecutive
months or more after registration), died (patients
who died due to TB or other causes before or dur-
ing treatment), and transferred out (patients whose
treatment results were unknown due to emigration
before or during treatment). For treatment-failure
patients, the subsequent regime was tailored in-
dividually according to clinical conditions and
drug-susceptibility tests. A regime containing at
least four effective drugs, including second-line
anti-tuberculosis agents, was given for 18 to 
24 months in accordance with the WHO guide-
line of MDR-TB.21 Only patients who followed the
treatment protocol were included for analysis. The
study was approved by the Human Experiment
and Ethics Committee of National Cheng-Kung
University Hospital. Written informed consent
was obtained from all patients.
Mycobacterial strain genotyping
To compare the differences between mycobac-
terial strains in the DMTB and TB groups, 62 
(30 DMTB, 32 TB) randomly collected isolates of
Mycobacterium tuberculosis were genotyped. Spoli-
gotyping was done according to the manufacturer’s
instructions (Isogen Bioscience B.V., Maarsen,
Holland). The resulting spoligotypes were docu-
mented using a binary code representing either a
positive or negative hybridization result and ana-
lyzed using Microsoft Excel to group and order
the patterns.22
Statistical analysis
Data are expressed as percentages for categorical
factors and as means± standard deviations for con-
tinuous factors. Comparisons between the DMTB
and TB groups used the χ2 or Student t test, as
appropriate. Cumulative incidences of persistent
positive sputum mycobacterial cultures over time
were analyzed using Kaplan-Meier product limit
estimates, and comparisons between groups was
performed using the log rank test. Potential pre-
dictors for treatment failure at 6 months were
evaluated using logistic regression. Statistical sig-
nificance was set at p < 0.05, two-sided. Data
were analyzed using SPSS version 12.0 (SPSS
Inc., Chicago, IL, USA) and STATA version 8.0
(StataCorp, College Station, TX, USA).
Results
Clinical manifestations
From November 2004 to October 2005, 438 pa-
tients with culture-proven pulmonary TB (in-
cluding newly diagnosed and previously treated
patients) were diagnosed and treated at the Chest
Hospital, Tainan, Taiwan. Among them, 129
(29.5%) patients had DM and 309 (70.5%) had
TB alone. There were significantly more male pa-
tients in both groups. The mean age was similar
in both groups. There were 67 (15.3%) multidrug-
resistant tuberculosis (MDR-TB) patients in these
438 cases. A higher percentage of patients in the
DMTB group, than in the TB group had MDR-TB.
Except for gender, none of the other characteris-
tics was significantly different (Table 1).
Because some of these 438 patients had been
previously treated in other hospitals before being
recruited in this study, we prospectively recruited
newly diagnosed patients who were treated for the
first time and completed a treatment course (at
least 6 months), and were regularly followed-up
for a full year in our hospital. Patients who inter-
rupted their treatment for two or more consecutive
months, died during treatment, or were transferred
out after registration were excluded from further
analysis. Thus, we excluded 18 DMTB (12 defaulted
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treatment, 4 died, and 2 transferred out) and 59
TB (32 defaulted treatment, 9 died, and 18 trans-
ferred out) patients. In all, 192 new patients (60
DMTB; 132 TB) met all the criteria and were in-
cluded for further analysis (Figure 1). Two DMTB
patients and nine TB patients associated with pleu-
ral effusion during the diagnosis of pulmonary
TB (3.3% vs. 6.8%, p = 0.336). No other extrapul-
monary TB infection was found.
In the DMTB group, the mean duration of di-
abetes was 5.0 ± 5.1 years, and the mean initial
HbA1c at the time of TB diagnosis was 10.0±2.6%
(based on 42 patients with concurrent results).
Among the DMTB patients, 52 patients were di-
agnosed as DM before the TB diagnosis and eight
patients were diagnosed at the time when the di-
agnosis of TB was made. Fifty-six patients (93%)
were treated with oral hypoglycemic agents, in-
sulin injection, or both; the remaining four pa-
tients received diet control only. The ages of the
DMTB and TB patients were comparable. As in
the original group, there were significantly more
men than women in both subgroups, especially
DMTB patients (Table 2). One patient with DM
Table 1. Characteristics of 438 patients with culture-positive pulmonary tuberculosis
Characteristics DMTB (n = 129) TB (n = 309) p
Sex, men (%) 84 71 0.006
Mean age ± SD (yr) 57.9 ± 12.8 57.2 ± 18.8 0.701
Previously treated cases, n (%) 51 (39.5) 118 (38.2) 0.792
MDR-TB, n (%) 26 (20.2) 41 (13.3) 0.068
Newly diagnosed cases, n (%) 78 (60.5) 191 (61.8) 0.792
MDR-TB, n (%) 0 0
SD = standard deviation; MDR-TB = multidrug-resistant TB; DMTB = pulmonary tuberculosis patient comorbid with type 2 diabetes
mellitus; TB = pulmonary tuberculosis patient not comorbid with type 2 diabetes mellitus.
Figure 1. Initially, 438 culture-proven pulmonary tuberculosis (TB) patients were diagnosed during the study period.
Among them, 169 patients had received TB treatment before the study. In 269 newly diagnosed TB patients, only 192
patients were enrolled and analyzed after finally excluding defaulted, deceased, or transferred out patients.
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169 Previously treated patients
Patients without 
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Newly diagnosed
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44 patients were
excluded due to
defaulted treatment
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20 patients were excluded due to transferred out
Regularly treated, followed patients
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and two without had established end-stage kid-
ney failure for > 3 months. The average body
mass index (BMI) was higher in the DMTB group
(Table 2). The DMTB patients had higher leuko-
cyte counts, more severe chest radiograph mani-
festations, a higher proportion of cavitary lesions
and positive sputum AFB, and heavier mycobac-
terial loads (Table 2). All these data indicated that
DMTB patients had more severe infections at the
time of diagnosis. Before treatment, there was no
significant difference in the proportion of primary
first-line drug resistance between the two groups
(Table 2).
Treatment outcomes
After treatment, 50 (83%) DMTB and 119 (90%)
TB patients had been cured or completed treat-
ment within one year. However, DMTB patients
needed significantly longer treatment to be cured,
to complete treatment, and to achieve sputum
conversion (Table 3). After the first 6 months of
treatment, 10 DMTB and two TB patients who
could not be treated successfully were classified
as bacteriological treatment failures. They needed
regimen adjustments and could not complete the
treatment within one year. Among them, eight
DMTB and two TB patients had positive mycobac-
terial culture results during the 5th month of treat-
ment. The remaining two DMTB patients had
positive AFB results on their sputum smears in
the 6th month of treatment. Additional investiga-
tion of those patients with bacteriological treat-
ment failure at 6 months showed that three DMTB
patients and one TB patient had developed MDR-
TB 1 year after starting treatment. These four pa-
tients were the only ones who had still not
achieved sputum conversion after 1 year of treat-
ment. The initial mean HbA1c of these eight DMTB
patients was 10.3 ± 3.6% and it was 8.6 ± 2.4%
after a treatment course. Meanwhile, the initial
mean HbA1c of those three DMTB patients who
developed MDR-TB was 11.9 ± 2.1% and it was
9.3 ± 3.8% after a treatment course. Another 11
patients in the TB group needed treatment for
more than 1 year because of the adverse effects of
anti-tuberculosis treatment, rather than the failure
Table 2. Characteristics of 192 patients with newly diagnosed and regularly treated pulmonary tuberculosis
Characteristics DMTB (n = 60) TB (n = 132) p
Sex, men (%) 82 67 0.042
Mean age ± SD (yr) 56.6 ± 12.7 57.5 ± 20.7 0.782
BMIa (kg/m2) 21.8 ± 3.2 20.5 ± 3.3 0.022
Leukocyte countb (× 103/mL) 9.4 ± 4.1 8.0 ± 2.8 0.008
Chest radiograph severity < 0.01
Far-advanced 27/60 30/132
Moderately-advanced 28/60 80/132
Mild 5/60 22/132
Cavitary lesion, n (%) 45/60 (75) 63/132 (48) < 0.01
Sputum AFB positive, n (%) 53/60 (88) 78/132 (59) < 0.01
Mycobacterial load (+)c 2.9 ± 1.3 1.9 ± 1.7 < 0.01
Primary drug resistance, n (%) 10/60 (17) 17/132 (13) 0.484
Isoniazid resistance 10 17
Rifampicin resistance 0 0
Ethambutol resistance 0 0
aOnly 50 DMTB and 97 TB patients were calculated; bonly 57 DMTB and 123 TB patients were calculated; cthe mycobacterial load was
graded as +, ++, +++, or ++++, according to the grading of the CDC-USA. DMTB=pulmonary tuberculosis patient comorbid with type 2 di-
abetes mellitus; TB = pulmonary tuberculosis patient not comorbid with type 2 diabetes mellitus. SD = standard deviation; MDR-TB =
multidrug-resistant tuberculosis; BMI = Body mass index; AFB = acid-fast bacilli.
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of bacteriological treatment. Although a regimen
containing at least four effective drugs (including
second-line anti-tuberculosis agents) had been
given to MDR-TB patients, one DMTB patient with
thick-wall cavitary lesions needed surgical resec-
tion to achieve sputum conversion after the 1-year
period. A Kaplan-Meier curve of comparisons of
the monthly mycobacterial culture results during
follow-up showed that mycobacteria from DMTB
patients had a higher probability of delayed clear-
ance than those from TB patients (Figure 2, log-
rank test, p<0.01). All the patients became sputum
culture-negative 15 months after the initiation of
anti-TB treatment. In univariate analysis for poten-
tial predictors, DM and chest radiograph severity
were significantly associated with treatment fail-
ure at 6 months (Table 4). A multivariate logistic
regression analysis on DM and chest radiograph
severity revealed that DM is the major contribut-
ing factor for treatment failure (Table 4).
Using spoligotype analysis to genotype
mycobacterial strains
Sixty-two mycobacterial samples from 30 DMTB
and 32 TB patients, including the three samples
from the DMTB patients who eventually devel-
oped MDR-TB, were analyzed (Table 5). The spo-
ligotype genotyping data revealed that 44% were
Beijing type, 13% were East-African-Indian (EAI)
type, 13% were Haarlem (H) type, 6% were
MANU type, 5% were T type, 3% were U type,
and 16% were Orphan (unclassified) type. The re-
sults showed similar proportions of Beijing and
non-Beijing types in DMTB and TB patients. Of
the bacterial strains from the three DMTB patients
who developed MDR-TB, two were Beijing type
and one was Orphan type.
Discussion
Although type 2 DM has long been recognized as
a risk factor of TB, its effects on the clinical picture
and treatment response is still poorly understood.
In this study, we first performed a one-year cross-
sectional investigation of pulmonary TB patients.
There was a higher percentage of MDR-TB patients
in the DMTB group than in the TB group, which
is in accordance with other studies.14 We then fo-
cused our investigation on newly diagnosed pa-
tients who had never before been treated for TB.
Our prospective study on these TB patients with
and without DM provided a unique chance to
observe the differences in disease characteristics
and treatment response during the first year of
treatment.
A recently published Indonesian study23 re-
ported that DMTB patients presented with more
symptoms, but not more severe TB, which differs
from results in the present study. It was previously
reported1,24 that TB prevalence is much lower in
Taiwan than in Indonesia, and that the age distri-
bution of TB is apparently different in these two
countries. Our patients in both groups were signi-
ficantly older than those in the Indonesian study,
in which the TB-only group was much younger
Table 3. One-year outcomes of patients with newly diagnosed and regularly treated pulmonary tuberculosis
DMTB (n = 60) TB (n = 132) p
Cured and completed treatmenta, n (%) 50/60 (83) 119/132 (90) 0.177
Duration of treatmentb (mo) 9.9 ± 1.8 (n = 50) 7.5 ± 1.8 (n = 119) < 0.01
Treatment failure (at 5–6 mo), n (%) 10/60 (17) 2/132 (2) < 0.01
culture/smear positive 8/2 2/0
Sputum conversion (mo) 2.5 ± 3.0 1.6 ± 1.4 < 0.01
MDR-TB, n (%) 3/60 (5.0) 1/132 (0.8) 0.056
a11 patients in TB group needed treatment after one year due to adverse effect of anti-TB drugs; bonly those who were cured and com-
pleted-treatment within one year were calculated. Cured = finished treatment with negative bacteriology result at the end of treatment;
completed treatment = finished treatment, but without bacteriology result at the end of treatment; failure = remaining culture positive
at 5 months or sputum acid-fast bacilli (AFB) positive at 6 months despite correct intake of medication; DMTB = pulmonary tuberculo-
sis patient comorbid with type 2 diabetes mellitus; TB = pulmonary tuberculosis patient not comorbid with type 2 diabetes mellitus.
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than the DMTB group. Because age-dependent
host-responses to mycobacteria are likely to cause
different clinical manifestations via different im-
munopathogenic mechanisms,25 the apparent dif-
ference in the ages of the TB and DMTB groups in
the Indonesian study may make comparison be-
tween them difficult. Therefore, our study has the
advantage of providing two groups of patients with
comparable demographic backgrounds and better
reflects the effects of diabetes on pulmonary TB.
Although the percentage of DMTB patients in our
study (60/192, 31.3%) was higher than that re-
ported in other studies performed in other coun-
tries, similar numbers were reported in two recent
Taiwanese studies26,27 from a medical center and
a regional hospital in southern Taiwan (74/217,
34.1% and 91/343, 26.5%). Thus, it is unlikely
that the high DMTB/TB ratio in the present study
reflects a referral bias. Moreover, because our
groups of TB-only and DMTB patients showed
similar distributions of bacterial strains and pri-
mary resistance rates, the clinical severity repre-
sented by the higher percentage of more severe
chest lesions and mycobacterial loads can be more
reasonably attributed to diabetes in the DMTB
group. Our multivariate logistic regression analysis
also indicated DM as a more important contribut-
ing factor of treatment failure.
We showed that there is a higher chance of TB
bacilli persistence in the sputum in the DMTB
Table 4. Analysis for predictors of treatment failure in patients with pulmonary tuberculosis
Characteristics Treatment failure (n = 12) Non-treatment failure (n = 180) p
Sex, men (%) 75 72 0.804
Mean age ± SD (yr) 59.5 ± 15.8 57.1 ± 18.8 0.664
BMIa (kg/m2) 20.0 ± 3.2 21.0 ± 3.3 0.297
Type 2 DM, n (%) 10 (83) 50 (28) < 0.01
Diabetic status
Duration (yr) 6.0 ± 6.0 4.7 ± 5.0 0.462
HbA1cb (%) 9.4 ± 3.8 10.2 ± 2.3 0.455
Treatment
Diet control 1 3
OHA and/or insulin 9 47
Leukocyte countc (×103/mL) 8.0 ± 2.3 8.5 ± 3.4 0.584
Primary drug resistance, n (%) 3 (25) 24 (13) 0.260
Chest radiograph severity
Far advanced 7 50 0.025
Moderately advanced 4 104 0.098
Mild 1 26 0.555
Cavitary lesion, n (%) 9 (75) 99 (55) 0.176
Sputum AFB positive, n (%) 10 (83) 121 (67) 0.246
Mycobacterial load (+)d 2.8 ± 1.6 2.2 ± 1.7 0.269
Multivariate regression analysis for DM and far-advanced CXR on treatment failure
Variable Odds ratio 95% CI p
DM 10.91 2.26–52.76 0.003
Far advanced CXR 2.29 0.65–8.03 0.195
aOnly 12 treatment-failure and 135 non-treatment-failure patients were calculated; bonly 8 treatment-failure and 34 non-treatment-failure
patients were calculated; conly 12 treatment-failure and 168 non-treatment-failure patients were calculated; dmycobacterial load,
graded as +, ++, +++, or ++++, according to the grading of CDC-USA. SD = standard deviation; DM = diabetes mellitus; HbA1c =
hemoglobin A1c; BMI = Body mass index, measured by weight in kilograms divided by the square of height in meters; OHA = oral 
hypoglycemic agent; AFB = acid-fast bacilli. CXR = chest X-ray. CI = confidence interval.
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group than in the TB-only group after 5 months
of treatment, and that this persistence made it
necessary for more patients with diabetes to be
treated for more than one year. DMTB patients
needed a longer period for sputum conversion.
Further statistical analysis confirmed that type 2
DM and the severity of TB were the only related
factors of treatment failure in this study. Because
we found more severe TB in our patients, we con-
clude that type 2 DM was the major cause of poor
treatment outcomes in DMTB patients. Previous
studies showed that a major mechanism for the
emergence of drug resistance in TB bacilli is ran-
dom mutation in the bacterial genome and the
pressure of selection by anti-tuberculosis drugs.
Pulmonary TB patients with higher mycobacte-
rial loads at the initiation of treatment hence may
have higher chance of bacillary mutation and the
emergence of MDR-TB.28 Given that our DMTB
patients had higher bacterial loads and needed
longer treatment to clear the bacteria, it hence
should not be surprising that a higher chance of
MDR-TB was observed in the DMTB patient group.
Although DOTS had not been implemented when
this prospective follow-up study was performed,
the high successful treatment rate in both groups
and the conversion of sputum after intensive treat-
ment in all treatment-failure and MDR-TB patients
indicate that compliance should not be a signifi-
cant factor for the different treatment outcomes
in this study. Previous genotyping studies29,30 of
Mycobacterium tuberculosis showed that the major
spoligotypes found in Taiwan include Beijing line-
ages (44.4–52.5%), Haarlem lineages (13.5%),
and EAI plus EAI-like lineages (11%). An asso-
ciation between drug resistance and the Beijing
genotype has been well documented.31,32 As our
spoligotype genotyping results in both the TB-
only and DMTB groups is in line with previous
reported distributions of mycobacterial strains in
this country, our results further indicate that the
difficulty in treatment and poorer outcome of
DMTB patients should be attributed to different
host factors in TB-only and DMTB patients rather
than to different mycobacterial strains. However,
there are several limitations in this study. Although
we prospectively followed up the patients, our ob-
servations were based on a cross-sectional study
design in a single referral center, which precludes
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Figure 2. The probability of a positive sputum culture of
Mycobacterium tuberculosis (TB) during anti-TB treatment
[60 patients with pulmonary TB comorbid with type 2 DM
(DMTB) and 132 pulmonary tuberculosis patients not co-
morbid with type 2 DM (TB) patients]. After the treatment
had begun, mycobacterial culture results were collected
and compared monthly. The percentage of patients posi-
tive for sputum TB cultures in the DMTB (--) and TB (—)
groups are shown. The DMTB group shows delayed clear-
ance of mycobacteria compared with the TB-only group
(p = 0.006).
Table 5. Characteristics and spoligotypes of collected
Mycobacterium tuberculosis isolates from
62 pulmonary tuberculosisa
Characteristics
DMTB TB 
p
(n = 30) (n = 32)
Sex, men (%) 73 69 0.691
Mean 55.4 ± 13.2 52.1 ± 19.3 0.438
age ± SD (yr)
Beijing, n (%) 14 (46.7) 13 (40.6) 0.632
Non-Beijing, 16 (53.3) 19 (59.4) 0.632
n (%)
EAI 6 (20.0) 2 (6.3)
MANU 4 (13.3) 0
Haarlem 0 8 (25.0)
T 0 3 (9.4)
U 1 (3.3) 1 (3.1)
Orphan 5 (16.7) 5 (15.6)
a62 (30 DMTB and 32 TB) collected Mycobacterium tuberculosis iso-
lates of pulmonary TB patients were analyzed using spoligotyping:
Beijing lineages (44%); EAI (13%); and Haarlem lineages (13%). Ten
isolates could not be classified (Orphan; 16%). SD= standard deviation;
DMTB = pulmonary tuberculosis patient comorbid with type 2 DM;
TB = pulmonary tuberculosis patient not comorbid with type 2 DM;
EAI = East-African-Indian.
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us from understanding the causal relationship
between DM and severity of TB from the early stage
of the infection. This may hamper the clarification
of the role of DM in the early host response to
TB, which may lead to major differences in chest
X-ray severity and initial bacterial load that we
clearly revealed in this study. We are currently
working on animal models and in vitro leukocyte
stimulation tests to directly address these ques-
tions. A long-term cohort study on subjects with
or without DM for assessing the incidence of TB
and MDR-TB is required to obtain definite answers
to these questions.
Given the rapidly increasing number of pa-
tients with TB, it is apparently critical to investi-
gate the mechanisms that lead to poor treatment
outcomes in DMTB patients. A pharmacokinetic
study noted that plasma levels of rifampicin were
53% lower in DMTB than TB patients, which
might affect treatment outcomes.33 Moreover, the
immune response of the host may also be impor-
tant in this negative effect of diabetes. Tsukaguchi
et al34 showed a depressed production of IFN-γ
in DMTB patients and related this decrease in im-
mune response to poor DM control. Our recent
investigations (unpublished data) revealed a de-
pressed IL-12 response to mycobacterial stimu-
lation in leukocytes from DMTB patients and
suggested a compromised innate immune reaction
in these patients. Therefore, a compromised im-
mune function related to diabetes should be con-
sidered an important contributor to the initial
severity and poor treatment outcome in DMTB
patients. Additional mechanistic studies are hence
worthwhile to unravel the influence of type 2
DM on the host defense against TB.
In conclusion, this study showed that DMTB
patients had more severe infections, higher my-
cobacterial loads, higher treatment failure rates,
delayed clearance of mycobacteria, and poten-
tially higher probabilities of developing MDR-TB
than did TB-only patients. Our data suggest that
pulmonary TB patients complicated with type 2
DM may need to be treated with a more intensive
anti-TB regimen and be carefully followed-up for
MDR-TB.
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